MediciNova, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yuichi Iwaki
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4275 Executive Square La Jolla CA United States of America 92037
- IPO Date
- Dec 8, 2006
- CIK
- 0001226616
- Website
- medicinova.com
- Similar Companies
- Business
- MediciNova, Inc. is a biopharmaceutical firm dedicated to the discovery and advancement of innovative small-molecule therapies for severe medical conditions addressing significant unmet needs, primarily in the United States. The company's pipeline features MN-166 (ibudilast), an oral compound exhibiting both anti-inflammatory and neuroprotective effects, currently undergoing advanced development for various neurological conditions. This includes treatment for progressive multiple sclerosis, where it is Phase 3-ready and has secured relevant patents, as well as amyotrophic lateral sclerosis (ALS), for which its Phase 2b/3 COMBAT-ALS clinical trial recently completed enrollment, with an Expanded Access Program also underway, supported by NIH funding. Further indications for MN-166 extend to chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, Long COVID, substance dependence and addiction, and the prevention of acute respiratory distress syndrome. Another key candidate is MN-001 (tipelukast), an orally available small molecule targeting fibrotic and metabolic disorders. It is being investigated for conditions such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, with a Phase 2 trial recently completing enrollment for the latter. The pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for managing acute exacerbations of asthma and chronic obstructive pulmonary disease. Additionally, MN-029 (denibulin), a vascular-disrupting agent, has completed Phase 1 studies for the treatment of solid tumor cancers. MediciNova leverages strategic collaborations, predominantly with Japanese pharmaceutical entities, to advance its diversified portfolio. The company, established in 2000, maintains its headquarters in La Jolla, California.
Company News
MediciNova, Inc. (NASDAQ:MNOV) Stock Has Average Target Price of $7.75
MediciNova (NASDAQ:MNOV) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s Why
MediciNova to Participate in the Maxim Growth Summit
Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
MediciNova to Participate in Two Investor Conferences in September
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova CEO Provides Shareholder Update
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened
MediciNova to Participate at the 38th Annual ROTH Conference
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts